基于整合药理学及分子对接技术探讨小青龙汤治疗慢性阻塞性肺疾病急性加重期的分子机制

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (1838 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的借助整合药理学与分子对接技术探讨小青龙汤治疗慢性阻塞性肺疾病急性加重期（AECOPD）的分子机制。方法通过中医药整合药理学平台V2.0检索小青龙汤的药物成分和靶标，运用GeneCards、OMIM数据库查找疾病靶标，运用STRING数据库构建蛋白质-蛋白质相互作用网络，运用Cytoscape 3.7.2构建“方剂-活性成分-核心靶标-表型-疾病”多维网络图。运用AutoDock软件对活性成分与核心靶标进行分子对接。结果获得小青龙汤治疗AECOPD的潜在活性成分41个，核心靶标23个。基因本体和京都基因和基因组数据库富集分析显示，核心靶标多参与炎症免疫、氧化应激、能量代谢等生物学过程。分子对接显示芍药二酮、异甘草素、2，4，4’-三羟基查耳酮与表皮生长因子、Akt激酶1、肿瘤坏死因子具有较高亲和力。结论初步筛选出小青龙汤治疗AECOPD的潜在活性成分及作用靶标，其多成分、多靶点作用主要通过炎症免疫、氧化应激及能量代谢等生物过程改善AECOPD进程。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	韩东卫杨琴琴王利芳梁欣张洪波张维君

关键词 ：整合药理学, 小青龙汤, 慢性阻塞性肺疾病急性加重期, 分子对接

Abstract：Objective To explore the molecular mechanism of Xiaoqinglong Decoction in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) by integrating pharmacology and molecular docking technology. Methods Components and targets of Xiaoqinglong Decoction were retrieved by integrative pharmacology-based research platform of traditional Chinese medicine V2.0 database, and the targets related to AECOPD were queried by using GeneCards and OMIM databases. Protein-protein interaction network was performed by using STRING database. The multidimensional network diagram of “prescription-active ingredient-core target-phenotype-disease” was constructed by using Cytoscape 3.7.2 software. The active ingredients and the core targets were performed to molecular docking by using AutoDock software. Results A total of 41 components and 23 core targets of Xiaoqinglong Decoction were retrieved. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis indicated that core targets were mostly involved in biological processes such as inflammation and immunity, oxidative stress, and energy metabolism. Molecular docking showed that paeoniflorin dione, isoglycyrrhizin, and 2，4，4’-trihydroxychalcone had high affinity with epidermal growth factor, Akt kinase 1, and tumor necrosis factor. Conclusion The potential active components and targets of Xiaoqinglong Decoction in the treatment of AECOPD are initially screened, its multi-component and multi-target effects mainly improve AECOPD process through biological processes such as inflammation and immunity, oxidative stress, and energy metabolism.

Key words： Integrative pharmacology Xiaoqinglong Decoction Acute exacerbation of chronic obstructive pulmonary disease Molecular docking

基金资助:国家自然科学基金资助项目（81904090）；
黑龙江省自然科学基金项目（YQ2021H026）；
黑龙江中医药大学“优秀创新人才支持计划”科研项目。

通讯作者: 张维君（1985.11-），女，博士，主要从事方剂药效分子机制研究。

作者简介: 韩东卫（1987.6-），男，博士，主要从事方剂药效及作用机制研究。

引用本文:

韩东卫杨琴琴王利芳梁欣张洪波张维君. 基于整合药理学及分子对接技术探讨小青龙汤治疗慢性阻塞性肺疾病急性加重期的分子机制[J]. 中国医药导报, 2022, 19(10): 20-24.
HAN Dongwei YANG Qinqin WANG Lifang LIANG Xin ZHANG Hongbo ZHANG Weijun. Discussion on the molecular mechanism of Xiaoqinglong Decoction in the treatment of acute exacerbation of chronic obstructive pulmonary disease based on integrative pharmacology and molecular docking technology#br#. 中国医药导报, 2022, 19(10): 20-24.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I10/20

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南（2021年修订版）[J].中华结核和呼吸杂志，2021，44（3）：170-205.
[2] Ritchie AI，Wedzicha JA. Definition，Causes，Pathogenesis，and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations [J]. Clin Chest Med，2020，41（3）：421-438.
[3] 熊珊珊，李鹏.中西医结合治疗慢性阻塞性肺疾病急性加重期痰浊阻肺型临床观察[J].实用中医药杂志，2020， 36（12）：1584-1585.
[4] 钟连江，张连生，顾春枫，等.小青龙汤联合无创呼吸机治疗对老年AECOPD患者PCT、血气分析及呼吸功能的影响及临床意义[J].中国中药杂志，2018，43（14）：3026-3030.
[5] Kotlyarov S，Kotlyarova A. Molecular Mechanisms of Lipid Metabolism Disorders in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease [J]. Int J Mol Sci，2021，22（14）：7634.
[6] Zinellu E，Zinellu A，Fois AG，et al. Oxidative Stress Bio-markers in Chronic Obstructive Pulmonary Disease Exac- erbations：A Systematic Review [J]. Antioxidants（Basel），2021，10（5）：710.
[7] Zhao X，Wu Y. Correlations of Silent Information Regulator of Transcription 1（SIRT1）Expression，Inflammatory Factors，and Oxidative Stress with Pulmonary Function in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease（AECOPD）[J]. Med Sci Monit，2021， 27：e929046.
[8] 张传涛，肖玮，陈科伶，等.基于“伏邪”理论探讨小青龙汤治疗COPD急性发作期的临床疗效[J].时珍国医国药，2020，31（11）：2693-2695.
[9] Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease [J]. Nat Rev Drug Discov，2013，12（7）：543-559.
[10] Kubysheva N，Boldina M，Eliseeva T，et al. Relationship of Serum Levels of IL-17，IL-18，TNF-α，and Lung Function Parameters in Patients with COPD，Asthma-COPD Overlap，and Bronchial Asthma [J]. Mediators Inflamm，2020，2020：4652898.
[11] Wei B，Tian T，Liu YG. IL-10 Combined with NGAL Has Diagnostic Value for AECOPD Combined with AKI [J]. Int J Chron Obstruct Pulmon Dis，2020，15：637-644.
[12] Huang Q，Yang H，Zhang C，et al. Xiaoqinglong Decoction Protects the Lungs of AECOPD Mice through the AMPK/mTOR Signaling Pathway [J]. Evid Based Complement Alternat Med，2020，2020：9865290.
[13] Xiao C，Cheng S，Li R，et al. Isoforskolin Alleviates AECOPD by Improving Pulmonary Function and Attenuating Inflammation Which Involves Downregulation of Th17/IL-17A and NF-κB/NLRP3 [J]. Front Pharmacol，2021，12：721273.
[14] 张月.小青龙汤加味对慢性阻塞性肺疾病急性发作期患者肺部功能及实验室指标的影响[J].现代中西医结合杂志，2020，29（12）：1323-1326.
[15] Sharif M，Esmaeil J，Ali A，et al. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy [J]. J Pathol，2021，254（5）：505-518.
[16] Pirozzi F，Ren K，Murabito A，et al. PI3K Signaling in Chronic Obstructive Pulmonary Disease：Mechanisms，Targets，and Therapy [J]. Curr Med Chem，2019，26（16）：2791-2800.
[17] Zhou L，Gu W，Kui F，et al. The mechanism and candidate compounds of aged citrus peel（chenpi）preventing chronic obstructive pulmonary disease and its progression to lung cancer [J]. Food Nutr Res，2021，17：65.
[18] 莫碧文，苏海英，韦江红，等.TLR4、p-Akt在哮喘大鼠气道平滑肌迁移的作用及小青龙汤对其影响[J].中国药理学通报，2011，27（5）：723-728.
[19] Soemarwoto RA，Putra AC，Mustofa S，et al. Decreased plasma epidermal growth factor（EGF）levels in patients with severe chronic obstructive pulmonary disease [J]. Pneumologia，2019，68（1）：21-26.
[20] Segura-Valdez L，Pardo A，Gaxiola M，et al. Upregulation of gelatinases A and B，collagenases 1 and 2，and increased parenchymal cell death in COPD [J]. Chest，2000，117（3）：684-694.
[21] 王虹，陈晓云，宁静，等.黄酮类化合物对免疫相关信号通路的调控作用研究进展[J].动物医学进展，2019，40（12）：102-105.
[22] Pandey KC，Sajal D，Mishra PK. Role of Proteases in Chronic Obstructive Pulmonary Disease [J]. Front Pharmacol，2017，8：512.
[23] Wang S，He N，Sun Y，et al. Function of hesperidin alleviating inflammation and oxidative stress responses in COPD mice might be related to SIRT1/PGC-1α/NF-κB signaling axis [J]. J Recept Signal Transduct Res，2020， 40（4）：388-394.
[24] 于维汉，何耀华.槲皮素在治疗骨关节炎中作用机制的研究进展[J].中华骨与关节外科杂志，2019，12（6）：477-480.
[25] Tsou YA，Huang HJ，Lin WW，et al. Lead Screening for Chronic Obstructive Pulmonary Disease of IKK2 Inhibited by Traditional Chinese Medicine [J]. Evid Based Complement Alternat Med，2014，2014：465025.
[26] Ni K，Cai X，Chen Y，et al. Determining Pharmacological Mechanisms of Chinese Incompatible Herbs Fuzi and Banxia in Chronic Obstructive Pulmonary Disease：A Systems Pharmacology-Based Study [J]. Evid Based Complement Alternat Med，2020，2020：8365603.